» Articles » PMID: 37102183

Utility of Endoscopic Ultrasound for Assessment of Locoregional Recurrence of Pancreatic Adenocarcinoma After Surgical Resection

Overview
Journal Endosc Int Open
Specialty Gastroenterology
Date 2023 Apr 27
PMID 37102183
Authors
Affiliations
Soon will be listed here.
Abstract

Up to 80 % of patients with pancreatic adenocarcinoma develop locoregional recurrence after primary resection. However, the detection of recurrent pancreatic ductal adenocarcinoma (RPDAC) after pancreatic surgery can be challenging because of difficulty distinguishing locoregional recurrence from normal postoperative or post-radiation changes. We sought to evaluate the utility of endoscopic ultrasound (EUS), in detecting pancreatic adenocarcinoma recurrence after surgical resection and its impact on the clinical management of patients. This was a retrospective study of all pancreatic cancer patients who underwent EUS post-resection at two tertiary care centers between January 2004 and June 2019. Sixty-seven patients were identified. Of these, 57 (85 %) were diagnosed with RPDAC, resulting in change in clinical management of 46 (72 %) patients. EUS identified masses not seen on computed tomography, magnetic resonance imaging, or positron emission tomography in seven (14 %). EUS is useful in detecting RPDAC after pancreatic surgery and can lead to significant impact on clinical management.

References
1.
Daamen L, Groot V, Heerkens H, Intven M, van Santvoort H, Molenaar I . Systematic review on the role of serum tumor markers in the detection of recurrent pancreatic cancer. HPB (Oxford). 2018; 20(4):297-304. DOI: 10.1016/j.hpb.2017.11.009. View

2.
Regine W, Winter K, Abrams R, Safran H, Kessel I, Chen Y . Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG oncology RTOG trial 9704. Adv Radiat Oncol. 2018; 3(2):154-162. PMC: 6000159. DOI: 10.1016/j.adro.2018.01.003. View

3.
Kim Y, Song K, Lee Y, Park K, Hwang D, Lee J . Management of isolated recurrence after surgery for pancreatic adenocarcinoma. Br J Surg. 2019; 106(7):898-909. DOI: 10.1002/bjs.11144. View

4.
Ikemoto J, Hanada K, Minami T, Okazaki A, Abe T, Amano H . Prospective Follow-up Study of the Recurrence of Pancreatic Cancer Diagnosed at an Early Stage: The Value of Endoscopic Ultrasonography for Early Diagnosis of Recurrence in the Remnant Pancreas. Pancreas. 2018; 47(4):482-488. DOI: 10.1097/MPA.0000000000001021. View

5.
Ko A, Hwang J, Venook A, Abbruzzese J, Bergsland E, Tempero M . Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer. 2005; 93(2):195-9. PMC: 2361548. DOI: 10.1038/sj.bjc.6602687. View